SCHEMBL5135876

SCHEMBL5135876

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(S(N)(=O)=O)cc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
TAS2R14 Q9NYV8 1/20 0.39
PTGES O14684 1/20 0.38
ALOX5 P09917 1/20 0.38
TSHR P16473 2/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
HSP90AA1 P07900 2/20 0.38
HSP90AB1 P08238 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
KMT2A Q03164 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651911 0.92 C5AR1 (0.56) C5AR1SMN1; SMN2LMNAL3MBTL1PTGS1
SCHEMBL650279 0.91 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1PTGS1
SCHEMBL5135929 0.91 C5AR1 (0.72) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL4767016 0.91 C5AR1 (0.75) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL1913036 0.91 C5AR1 (0.55) C5AR1SMN1; SMN2LMNAL3MBTL1PTGS1
SCHEMBL652179 0.89 C5AR1 (0.53) C5AR1SMN1; SMN2LMNAL3MBTL1PTGS1
SCHEMBL649522 0.88 C5AR1 (0.48) C5AR1SMN1; SMN2LMNAPTGS1PTGS2
SCHEMBL649255 0.88 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL649410 0.88 C5AR1 (0.47) C5AR1SMN1; SMN2LMNAPTGS1PTGS2
SCHEMBL649645 0.88 C5AR1 (0.70) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed